Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$1.07 USD

1.07
5,878,420

+0.05 (4.90%)

Updated May 14, 2024 04:00 PM ET

After-Market: $1.09 +0.02 (1.87%) 7:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

bluebird's Zynteglo Gets EU Conditional Marketing Approval

by Zacks Equity Research

bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.

Why Is Bluebird (BLUE) Down 15.1% Since Last Earnings Report?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y

by Zacks Equity Research

bluebird (BLUE) reports wider-than-expected Q1 loss. Nevertheless, the pipeline progress looks encouraging.

Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of -6.79% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

by Zacks Equity Research

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.

Is a Beat in the Cards for Molina's (MOH) Earnings in Q1?

by Zacks Equity Research

Molina Healthcare's (MOH) Q1 earnings will gain from membership growth and its streamlining efforts. However, the same might be partially offset by contract losses and the company's Marketplace business.

Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates

by Zacks Equity Research

Universal Health's (UHS) first-quarter earnings are affected by a pre-tax unrealized loss.

What's in Store for HCA Healthcare's (HCA) Q1 Earnings?

by Zacks Equity Research

HCA Healthcare (HCA) is likely to gain from higher admissions. However, escalating expenses might weigh down its margins.

Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings?

by Zacks Equity Research

WellCare Health's (WCG) first-quarter earnings are likely to gain from a rise in membership, partly offset by high debt load.

Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Tenet Healthcare (THC) is likely to be hit by declining revenues in the first quarter of 2019.

Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y

by Zacks Equity Research

Anthem's (ANTM) Q1 earnings surge on the back of a solid operating performance and strong growth across all core businesses.

Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Celgene & Acceleron Submit BLA for Luspatercept to the FDA

by Zacks Equity Research

Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.

Global Blood Focuses on Developing Lead Candidate Voxelotor

by Zacks Equity Research

Global Blood (GBT) is fast progressing on the development plans for its lead pipeline candidate, voxelotor for the treatment of sickle cell disease.

Celgene (CELG) Submits NDA for MS Drug to FDA for Review

by Zacks Equity Research

Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?

by Zacks Equity Research

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Celgene (CELG) Submits Application for MS Drug in Europe

by Zacks Equity Research

Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.

Sweta Killa headshot

Biotech ETFs Jump on Roche-Spark Deal

by Sweta Killa

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.

Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 3.89% and 96.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline

by Zacks Equity Research

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma

by Zacks Equity Research

AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.

Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

by Zacks Equity Research

Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.

Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.